G1 Therapeutics Inc (GTHX)
4.16
-0.12
(-2.80%)
USD |
NASDAQ |
Apr 18, 16:00
4.165
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 217.15M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 48.57% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.726 |
| Price to Book Value | 6.137 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.457 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.24% |
Profile
| G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy. |
| URL | https://www.g1therapeutics.com |
| Investor Relations URL | http://investor.g1therapeutics.com/ |
| HQ State/Province | North Carolina |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 01, 2024 |
| Last Earnings Release | Feb. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy. |
| URL | https://www.g1therapeutics.com |
| Investor Relations URL | http://investor.g1therapeutics.com/ |
| HQ State/Province | North Carolina |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 01, 2024 |
| Last Earnings Release | Feb. 28, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |